Approaches for 1L Therapy and Restaging in Triple-Positive mBC
Susan Dent, MD, delves into the exploration of front-line treatment options for triple-positive breast cancer and examines strategies for restaging in the event of disease progression after first-line therapy.
EP: 1.Advancements in Treatment Strategies for HER2+ Metastatic Breast Cancer: Insights from Experts at the Duke Cancer Center
Now Viewing
EP: 2.Approaches for 1L Therapy and Restaging in Triple-Positive mBC
EP: 3.The Role of Radiotherapy in HER2+ mBC
EP: 4.Treatment Approaches for Triple-Positive mBC in the 2L Setting and Beyond
EP: 5.Treatment Considerations and AE Management Strategies with HER2-Directed Therapies
EP: 6.Patient Case Presentation: A 34-Year-Old Woman with HER2+ mBC and Brain Metastases
EP: 7.HER2CLIMB: Targeting Stable and Active Brain Metastases in Advanced HER2+ Breast Cancer
EP: 8.BRIDGET: Preventing Secondary Brain Metastases in Advanced HER2+ Breast Cancer
EP: 9.Strategies for AE Management with Tucatinib in Breast Cancer
EP: 10.D-TORCH: Topical Diclofenac for Reducing Hand Foot Syndrome with Capecitabine
EP: 11.Patient Case Presentation: A 34-Year-Old Woman with HER+ mBC and Brain Metastases
EP: 12.Advancements in Treating Brain Metastases in HER2+ Breast Cancer
EP: 13.Radiation Necrosis with ADCs and Concurrent Radiotherapy for Brain Metastases
EP: 14.Strategies for AE Management with T-DXd in Breast Cancer
EP: 15.Looking Ahead: Future Perspectives and Unmet Need in HER+ Breast Cancer
EP: 16.Recent Data from KATHERINE and APHINITY in HER2+ Breast Cancer
EP: 17.Updates from HER2CLIMB in HER2+ Metastatic Breast Cancer
EP: 18.BRIDGET Study: Tucatinib Plus HER2-Directed Antibody Therapy in Breast Cancer
EP: 19.Future Perspectives on HER2+ Breast Cancer Treatment
EP: 20.Applying Updated Findings From SABCS 2023 to HER2+ Breast Cancer Practice
Recent Videos
Related Content
